The Wall Street Journal reports on the expected FDA approval of lenacapavir and what it might mean for Gilead's future in the market. Other coverage of science and research-related news is on a ...

Treatment should be stopped if nonarteritic anterior ischemic optic neuropathy, which can cause vision loss, is diagnosed.

A cheap over-the-counter supplement could hold the key to preventing heart failure in people with Type 2 diabetes, according ...

A post-hoc analysis of the pivotal CANVAS trial shows those receiving higher dose canagliflozin are more likely to experience the cardiovascular benefits associated with the drug.

GLP-1s are gaining interest for their impact on weight, blood sugar, and possibly mood in bipolar disorder. Here’s what ...

Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.